血清癌胚抗原（CEA）、糖类抗原19-9（CA19-9）和糖类抗原242（CA242）在胰腺癌诊断及预后中的临床价值

The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.

作者信息

Ni X G, Bai X F, Mao Y L, Shao Y F, Wu J X, Shan Y, Wang C F, Wang J, Tian Y T, Liu Q, Xu D K, Zhao P

机构信息

Department of Abdominal Surgery, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

出版信息

Eur J Surg Oncol. 2005 Mar;31(2):164-9. doi: 10.1016/j.ejso.2004.09.007.

DOI:10.1016/j.ejso.2004.09.007

PMID:15698733

Abstract

AIM

Serum tumour markers carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and CA242 were investigated to evaluate the values of single and combined test in the diagnosis and prognosis of pancreatic cancer.

METHODS

Pre-operative serum CEA, CA19-9 and CA242 were measured in 105 pancreatic cancers, 70 non-pancreatic malignancies and 30 benign pancreatic diseases.

RESULTS

The sensitivity of CA19-9 alone was the highest in pancreatic cancer patients (80%), but the specificity was significantly lower than that of CEA and CA242 (P<0.01). The combination of CEA and CA242 could increase the specificity to 92%. In serum CA242 positive patients, the survival time was remarkably shorter than that of patients with negative result (P<0.01). The survival time in patients with more than two markers positive expression of CEA, CA19-9 and CA242 was obviously shorter than that of only one or no marker positive expression (P<0.05).

CONCLUSION

The diagnostic rate of CA19-9 in pancreatic cancer is better than that of CEA and CA242. Combined detection of CEA and CA242 can improve the diagnostic specificity obviously. High levels of serum markers are associated with advanced stage of the disease. Patients with two or three markers positive expression of CEA, CA19-9, and CA242 simultaneously had a shorter survival time.

摘要

目的

研究血清肿瘤标志物癌胚抗原（CEA）、糖类抗原19-9（CA19-9）和CA242，以评估单项及联合检测在胰腺癌诊断及预后中的价值。

方法

检测105例胰腺癌患者、70例非胰腺恶性肿瘤患者及30例胰腺良性疾病患者术前血清CEA、CA19-9和CA242水平。

结果

胰腺癌患者中，单独检测CA19-9的敏感度最高（80%），但其特异度显著低于CEA和CA242（P<0.01）。CEA与CA242联合检测可使特异度提高至92%。血清CA242阳性患者的生存时间显著短于阴性患者（P<0.01）。CEA、CA19-9和CA242中两项及以上标志物呈阳性表达患者的生存时间明显短于仅一项或无标志物呈阳性表达的患者（P<0.05）。